Clinical implications of NRF3 mRNA and protein expression in ovarian cancer
BioImpacts · 27.10.2026 · 16 · 33746
DOI: 10.34172/bi.33746 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioImpacts, online erschienen am 27.10.2026. Verfasst von Mahdi Hosseinzadeh und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
The clinical role of the transcription factor NRF3 in ovarian cancer (OC) remains unclear, particularly regarding the relationship between its mRNA and protein levels. This study investigates NRF3 expression as a potential prognostic indicator in OC.
Methods
This multicenter study analyzed 171 archival FFPE ovarian cancer specimens (2015–2023) alongside 29 prospectively collected, snap-frozen cases (2021–2024). Samples included diverse histologic subtypes predominantly high-grade serous carcinoma with comprehensive FIGO staging and Silverberg grading. We quantified NRF3 expression via tissue microarrays and qPCR, correlating the results with clinicopathological data. Diagnostic and prognostic performance were assessed using ROC curves, Kaplan-Meier survival analysis, and Cox regression.
Results
NRF3 was significantly upregulated in OC, as evidenced by both increased mRNA levels (P = 0.021) and elevated IHC H-scores in tumor cores (P < 0.001). These high expression levels correlated with aggressive clinical markers, such as advanced FIGO stage, metastasis and recurrence (P < 0.001), and were predictive of poor overall and progression-free survival (P = 0.001). The prognostic value was further supported by ROC analysis, which yielded an AUC of 0.779 for relapse prediction.
Conclusion
NRF3 is consistently upregulated at both the mRNA and protein levels in ovarian cancer, with its accumulation strongly linked to advanced disease and poor survival, pointing to its role in stress-driven tumor invasiveness. As NRF3 expression lost independent significance in our multivariate analysis, we identify it primarily as a molecular marker of aggressive disease burden rather than an independent prognostic factor. Future work should focus on validating its potential utility within broader diagnostic panels.
Zitieren
APA
Hosseinzadeh, M., Madjd, Z., Rashid, M., Kalantari, E., Shokouhi, B., Sayyah-Melli, M., & Sadeghi, M. R. (2026). Clinical implications of NRF3 mRNA and protein expression in ovarian cancer. BioImpacts, 16, 33746. https://doi.org/10.34172/bi.33746
Vancouver
Hosseinzadeh M, Madjd Z, Rashid M, Kalantari E, Shokouhi B, Sayyah-Melli M, et al. Clinical implications of NRF3 mRNA and protein expression in ovarian cancer. BioImpacts. 2026;16:33746. doi:10.34172/bi.33746
BibTeX
@article{Hosseinzadeh2026,
author = {Hosseinzadeh, Mahdi and Madjd, Zahra and Rashid, Mohsen and Kalantari, Elham and Shokouhi, Behrooz and Sayyah-Melli, Manizheh and Sadeghi, Mohammad Reza},
title = {Clinical implications of NRF3 mRNA and protein expression in ovarian cancer},
journal = {BioImpacts},
year = {2026},
volume = {16},
pages = {33746},
doi = {10.34172/bi.33746}
}
EUVIMED